Following the discovery of hepatitis C virus (HCV), it was clear that a proportion of cases with acute and chronic hepatitis are still negative for all known viral markers, which prompted investigations to search for new hepatitis agents. In 1997 investigators in Japan isolated a DNA clone of a novel human virus using a representation difference analysis from serum samples from a patient (TT) with post-transfusion hepatitis of unknown etiology and designated TTV for transfusion-transmitted virus. TTV DNA is common in populations at increased risk for infection with hemophilia or maintenance hemodialysis and abusers of intravenous drugs. As a nonenveloped virus with a linear, single stranded genomic DNA, TTV resembles the Parvoviridae among known animal viruses. TTV has been reported in association with post-transfusion and acute and chronic hepatitis of unknown etiology. Phylogenetic analysis indicated six different genotypes of TTV with distinct subtypes [correction of sottotypes]. Viral DNA can be detected in plasma but also in liver tissue of infected subjects, suggesting that it is hepatotropic. TTV can be transmitted parenterally by blood and blood products and probably also non-parenterally by a fecal-oral route. TTV DNA is present in a large proportion of patients with different forms of non-A-G hepatitis. A new simple genotyping assay based on a restriction fragment length polymorphism of TTV was developed. This system will provide the framework for future detailed epidemiological and clinical investigations.
Download full-text PDF |
Source |
---|
Infect Disord Drug Targets
January 2025
HCA Healthcare Las Palmas/Del Sol Internal Medicine Program.
Background: Streptococcal Toxic Shock Syndrome (STSS) is a life-threatening condition caused by bacterial toxins. The STSS triad encompasses high fever, hypotensive shock, and a "sunburn-like" rash with desquamation. STSS, like Toxic Shock Syndrome (TSS), is a rare complication of streptococcal infec-tions caused by Group A Streptococcus (GAS), Streptococcal pyogenes (S.
View Article and Find Full Text PDFCirc Cardiovasc Interv
January 2025
Hospital Henri Mondor, Cardiologie, Creteil, France (T.T., A.S.T.-M., A. Molho, P.-M.C., P.Z., A.D.P., L.R., A. Mangiameli, E.T., M. Boukantar, R.G.).
J Glob Health
December 2024
Department of Anesthesiology, Critical Care and Pain Medicine, UTHealth, Houston, Texas, USA.
Background: Previous studies have shown that hypertonic saline nasal irrigation and gargling reduced the duration of symptoms in upper respiratory infections caused by coronavirus. This study aims to investigate the effects of two saline regimens on symptoms associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Methods: Between 2020 and 2022, individuals aged 18-65 years who tested positive for SARS-CoV-2 infection via polymerase chain reaction (PCR) were randomly assigned to either low- or high-saline regimens for 14 days.
CJC Open
February 2024
CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Background: Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.
Methods: Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42).
BMJ Oncol
September 2023
Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
Objective: Although adjuvant trastuzumab-based treatment (TBT) improves survival for patients with HER2-positive early invasive breast cancer (EIBC), risk of toxicity grows as patient age increases. We examined use of TBT and associated severe acute toxicity event (SATE) rates to understand the real-world impact.
Methods And Analysis: Women (50+ years), newly diagnosed with HER2-positive EIBC in England, 2014-2019, were identified from Cancer Registry data, linked to the Systemic Anti-Cancer Therapy dataset for TBT information.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!